Sartorius AG, a leading global partner of the biopharmaceutical industry, is headquartered in Göttingen, Germany. Founded in 1870, the company has evolved significantly, establishing a strong presence in Europe, North America, and Asia. Sartorius operates primarily in the life sciences and laboratory equipment sectors, focusing on bioprocess solutions and laboratory instruments. The company is renowned for its innovative products, including high-precision balances, bioreactors, and filtration systems, which are designed to enhance productivity and ensure quality in biopharmaceutical manufacturing. Sartorius has achieved notable milestones, such as its commitment to sustainability and digital transformation, positioning itself as a market leader. With a strong emphasis on research and development, Sartorius continues to drive advancements in the industry, making it a trusted name among scientists and manufacturers worldwide.
How does Sartorius's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Sartorius's score of 81 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Sartorius reported total carbon emissions of approximately 694,079,000 kg CO2e, with emissions distributed across various scopes: 20,355,000 kg CO2e (Scope 1), 51,872,000 kg CO2e (Scope 2), and 645,033,000 kg CO2e (Scope 3). The company has set ambitious targets to achieve significant reductions in its greenhouse gas emissions. Specifically, Sartorius aims to reduce avoidable Scope 1 and Scope 2 emissions to zero by 2030, which represents a 100% reduction. This commitment is contingent upon the availability of renewable energy at its global locations. Additionally, Sartorius has established a target to reduce CO2 emission intensity by an average of 10% per year by 2030, using 2019 as the baseline year. The company is also committed to achieving net climate neutrality across all its business activities by 2045. These initiatives reflect Sartorius's dedication to addressing climate change and minimising its environmental impact within the pharmaceuticals, biotechnology, and life sciences sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 11,044,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 18,632,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 |
Sartorius's Scope 3 emissions, which decreased by 25% last year and decreased by approximately 27% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 41% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sartorius has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Sartorius's sustainability data and climate commitments